HomeMarketsShares10x Genomics, Inc.

Trade 10x Genomics, Inc. - TXG CFD

Market is not available at the momentMarket information is presented
as of 2026-09-28T19:45:28+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.39
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.022262 %
(-$4.45)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.02226%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00004 %
($0.01)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


0.00004%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin5.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close85.5
Open85.27
1-Year Change631.3%
Day's Range84.94 - 89.18

Trade 10x Genomics, Inc. - TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Latest shares articles

Cellnex stock forecast
Cellnex stock forecast: BlackRock raises stake to 6.398%
Cellnex Telecom is a European telecom-infrastructure company listed in Madrid. In September, BlackRock raised its stake to 6.398% as Cellnex continued its share-buyback programme. Explore third-party CNLX price targets Past performance is not a reliable indicator of future results.
10 hours ago
Siemens stock forecast
Siemens stock forecast: VinSpeed high-speed rail contract
Siemens is a German industrial group with businesses across automation, infrastructure and mobility. On 22 September 2026, Siemens Mobility signed a high-speed rail contract with VinSpeed. Explore third-party SIE price targets. Past performance is not a reliable indicator of future results.
12 hours ago
DeFi Technologies stock forecast
DeFi Technologies stock forecast: Valour hedge fund launch
DeFi Technologies' subsidiary Valour launched its first hedge fund on 21 September 2026, expanding the business beyond exchange-traded products. Explore third-party DEFT price targets and technical analysis. Past performance is not a reliable indicator of future results.
13 hours ago
Buzzi Unicem logo displayed on a smartphone with a financial market chart in the background.
Buzzi stock forecast: H1 EBITDA and margin pressure
Buzzi is an Italian building-materials group listed in Milan, with recent trading shaped by a September share-price decline and a new investor presentation. Explore third-party BZU price targets and technical analysis. Past performance is not a reliable indicator of future results.
11:07, 25 September 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready